% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Wiesenfarth:266790,
      author       = {Wiesenfarth, Maximilian and Stamminger, Thomas and Zizer,
                      Eugen and Tumani, Hayrettin and Ludolph, Albert C},
      title        = {{N}eurological manifestation of {HEV} infection: still a
                      rare disease entity?},
      journal      = {Journal of neurology},
      volume       = {271},
      number       = {1},
      issn         = {0367-004X},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {DZNE-2024-00048},
      pages        = {386 - 394},
      year         = {2024},
      abstract     = {Hepatitis E virus (HEV) infection is the most common form
                      of viral hepatitis and is reported to cause neurological
                      manifestation in up to $30\%$ of diagnosed infections. We
                      evaluated the medical reports of all patients (n = 29,994)
                      who were discharged from the Department of Neurology of Ulm
                      University between 01.01.2015 and 30.09.2022 to detect
                      neurological manifestations of HEV. In addition, we
                      retrospectively analyzed the serum samples of n = 99
                      patients representing different neurological diseases
                      possibly related to HEV for anti-HEV-IgM and anti-HEV-IgG.
                      At the time of discharge from hospital, the etiology of
                      neurological symptoms in these patients was unclear.
                      Overall, five cases of extrahepatic neurological
                      manifestation of HEV (defined as anti-HEV-IgM and HEV-IgG
                      positive) could be detected. An increase of both, anti-IgM-
                      and anti-IgG-serum levels was significantly more common in
                      neuralgic amyotrophy/plexus neuritis/radiculitis than in
                      AIDP/CIDP (P = 0.01), meningitis/encephalitis (P = 0.02),
                      idiopathic peripheral facial paralysis (P = 0.02) and
                      tension headache (P = 0.02). In $15\%$ (n = 15 out of 99) of
                      retrospectively analyzed serum samples, conspicuous positive
                      anti-HEV-IgG levels were detected. This finding was most
                      common in AIDP/CIDP. In conclusion, results of this study
                      indicate neurological manifestation of HEV to be a rare but
                      still underestimated course of disease, occurring at any age
                      and gender. Therefore, testing for HEV should be considered
                      in patients with neurological symptoms of unknown origin,
                      especially in those with neuralgic amyotrophy/plexus
                      neuritis.},
      keywords     = {Humans / Hepatitis E virus / Brachial Plexus Neuritis:
                      diagnosis / Brachial Plexus Neuritis: etiology /
                      Retrospective Studies / Polyradiculoneuropathy, Chronic
                      Inflammatory Demyelinating: complications / Rare Diseases:
                      complications / Hepatitis E: complications / Hepatitis E:
                      diagnosis / Hepatitis Antibodies / Immunoglobulin M /
                      Immunoglobulin G / Guillain–Barré syndrome (Other) /
                      Guillain–Barré syndrome (Other) / Guillain–Barré
                      syndrome (Other) / Encephalitis (Other) / Guillain–Barré
                      syndrome (Other) / Hepatitis E virus (Other) / Neuralgic
                      amyotrophy (Other) / Neurological manifestation (Other) /
                      Plexus neuritis (Other) / Hepatitis Antibodies (NLM
                      Chemicals) / Immunoglobulin M (NLM Chemicals) /
                      Immunoglobulin G (NLM Chemicals)},
      cin          = {Clinical Study Center Ulm},
      ddc          = {610},
      cid          = {I:(DE-2719)5000077},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37737892},
      pmc          = {pmc:PMC10769984},
      doi          = {10.1007/s00415-023-11985-8},
      url          = {https://pub.dzne.de/record/266790},
}